Takeda Pharmaceutical Company (TAK)
NYSE:TAK
Want to see TAK full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.19Last Year’s EPS
0.26Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced strong R&D momentum, significant clinical successes and robust cash generation against near-term revenue pressures from VYVANSE loss of exclusivity, pricing and supply dynamics in plasma-derived therapies, and substantial transformation and launch investments that will weigh on FY2026 profit and EPS. Management presented a clear two‑horizon strategy: near-term transformation and investment to enable a wave of launches (Horizon One) followed by accelerated growth as the new products scale (Horizon Two). The pipeline success (3 positive Phase IIIs, priority reviews, TAK-881 data), disciplined cost savings (~JPY 300 billion captured to date) and solid free cash flow provide a foundation to absorb short-term headwinds and fund launches, while execution risks (resizing, restructuring costs, biosimilar/patent challenges and market dynamics in plasma products) are material but appear managed. Overall, positives from the pipeline and balance sheet outweigh the near-term financial and operational challenges, supporting a constructive outlook conditional on successful commercialization execution.Company Guidance
Robust Late‑Stage Pipeline and Clinical Success
Delivered 3-for-3 positive Phase III readouts (oveporexton, rusfertide, zasocitinib) in FY2025; TAK-881 showed positive pivotal results (20% facilitated SCIG, comparable efficacy to HYQVIA at half the Ig volume). Oveporexton and rusfertide granted FDA priority review with potential U.S. launches in H2 2026; zasocitinib planned for commercialization in H1 2027. Management expects this late-stage depth to be the most robust in Takeda's history and to support an average of 2–3 NME filings or major U.S. indication expansions per year through 2030.
Solid Core Financial Performance and Strong Cash Generation
FY2025 core revenue ~JPY 4.5 trillion (core revenue decline of 2.6% at CER), core operating profit JPY 1.17 trillion (down 0.9% at CER), core EPS JPY 517 (up 3.1% at CER). Reported operating profit JPY 408.8 billion (up 19.3%) and reported EPS JPY 122. Operating cash flow remained roughly in line with prior year (>JPY 1 trillion) and adjusted free cash flow was JPY 684.5 billion, supporting dividends, interest and near-term debt repayment plans.
Growth & Launch Products Driving Revenue Mix
Products categorized as Growth & Launch represent over 50% of revenue and grew 4.5% at CER in FY2025. Notable product performance included ENTYVIO +4.2% CER, FRUZAQLA +14.6% CER and QDENGA +10.7% CER (though QDENGA was behind forecast). IG grew 4.1% at CER with double-digit growth in subcutaneous Ig products highlighted as a key profitability driver for PDT.
Material Cost Savings and Efficiency Gains
Enterprise efficiency programs delivered approximately JPY 300 billion in gross annualized savings over two years, with over JPY 150 billion cost savings identified in FY2025 that largely offset LOE impact. Management expects the new transformation program to realize ~JPY 100 billion of savings in FY2026 and more than JPY 200 billion of annualized gross savings by FY2028.
Prudent Balance Sheet and Debt Management
Approximately JPY 500 billion of debt maturing in FY2026 planned to be repaid primarily from cash on hand and free cash flow; 100% of debt is fixed-rate with weighted average interest ~2.4%. Management targets deleveraging toward ~2.0x adjusted net debt/adjusted EBITDA and expects free cash flow (guidance JPY 650–750 billion for FY2026) to support capital allocation and dividend policy (annual dividend increased to JPY 204 per share).
Strategic Leadership Transition and Organizational Refresh
Planned CEO transition to Julie Kim with an updated executive team and a Board refresh (three proposed new members) intended to accelerate growth, simplify organization structure, centralize corporate functions and expand data/AI capabilities to drive speed and efficiency.
TAK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TAK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $16.42 | $16.64 | +1.34% |
Jan 29, 2026 | $16.69 | $17.17 | +2.88% |
Oct 30, 2025 | $13.77 | $13.23 | -3.92% |
Jul 29, 2025 | $14.31 | $14.32 | +0.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Takeda Pharmaceutical Company (TAK) report earnings?
Takeda Pharmaceutical Company (TAK) is schdueled to report earning on Jul 30, 2026, Before Open (Confirmed).
What is Takeda Pharmaceutical Company (TAK) earnings time?
Takeda Pharmaceutical Company (TAK) earnings time is at Jul 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TAK EPS forecast?
TAK EPS forecast for the fiscal quarter 2026 (Q1) is 0.19.